Table 2—

Effect of pioglitazone on mean lipoprotein and apolipoprotein levels in hypertensive patients

VariablePioglitazone (n = 26)
Placebo (n = 28)
P value
BaselineStudy end% ChangeBaselineStudy end% Change
Total cholesterol (mmol/l)5.2 ± 0.95.2 ± 0.9−05.1 ± 1.05.1 ± 1.0−0NS
Total triglycerides (mmol/l) (range)1.09 (0.58–7.13)1.36 (0.73–4.17)+251.42 (0.54–5.64)1.52 (0.43–9.53)+7NS
LDL cholesterol (mmol/l)2.8 ± 0.82.8 ± 0.6−02.8 ± 0.82.6 ± 0.8−7NS
HDL cholesterol (mmol/l)1.2 ± 0.31.3 ± 0.3+81.1 ± 0.31.1 ± 0.3−0NS
Total apoA-I (g/l)1.44 ± 0.221.36 ± 0.24−61.30 ± 0.381.34 ± 0.30+3NS
Total apoA-II (g/l)0.49 ± 0.100.51 ± 0.11+40.46 ± 0.090.45 ± 0.08−20.021
Total apoB (g/l)1.09 ± 0.231.00 ± 0.26−81.03 ± 0.331.06 ± 0.25+3NS
Total apoC-II (mg/l)40 ± 1747 ± 19+1846 ± 2046 ± 22+00.010
Total apoC-III (mg/l)120 ± 40126 ± 36+5129 ± 46125 ± 49−3NS
Total apoE (mg/l)29 ± 829 ± 7−032 ± 934 ± 12+6NS
ApoB in LDL (mg/l)824 ± 192767 ± 171−7803 ± 210796 ± 210−1NS
ApoB in dLDL (mg/l)*305 ± 141237 ± 140−22307 ± 116283 ± 132−80.024
  • Data are mean ± SD or median (range).

  • *

    * LDL-5 plus LDL-6. P values were calculated by Mann-Whitney U test for differences in percent change between the pioglitazone and the placebo group.